Researchers from the Wellcome Trust Sanger Institute system describe an insertional mutagenesis method that uses the PiggyBac transposon system to screen for cancer genes in mice.
At a conference in Australia today, researchers from Illumina and the Wellcome Trust Sanger Institute announced that they have sequenced the Tasmanian devil genome, along with tumor genomes representing a contagious cancer decimating wild devil populations.
The recently-completed 2010 Leena Peltonen School of Human Genomics was named in honor of the Finnish geneticist and head of the Wellcome Trust Sanger Institute's human genetics program who died in March.
The UK-based firm will provide Sanger with more than 200 genetically defined cell lines with cancer-causing mutations, which will guide researchers working on the Genomics of Drug Sensitivity in Cancer project.
The collaboration will provide Horizon's X-Man cancer models to the Genomics of Drug Sensitivity in Cancer project between Sanger and the University of Massachusetts General Hospital.
So far, Illumina has shipped more than 100 HiSeq instruments for revenue, representing "the fastest instrument scale-up in the company's history for the most complex product it has ever built."
The company has expanded its early-access program to a “limited number” of sites outside North America. It previously said it is interested in having testing sites in Europe and Asia.
Daniel Turner, Elizabeth Brady, Emily Winn-Deen, Melina Cimler, Tristan Orpin, Terry Pizzie, Ajay Bansal, John Curson, Ken Prokuski, Lewis Shuster, Stephen McLean
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.
